Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

Mise à jour : Il y a 4 ans
Référence : NCT02892123

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the maximal tolerated dose (MTD), optimal biological dose (OBD) or other recommended dose (RD), and overall safety and tolerability of ZW25, a humanized bispecific monoclonal antibody targeting the extracellular domain of HER2, in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.


Critère d'inclusion

  • HER2-expressing Cancers

Liens